Tumori最新文献

{"title":"Modern approaches to target tumor heterogeneity: Integrating technology and treatment.","authors":"Amit Kumar, Nisha Manav, Mayank Singh, Abhishek Shankar, Manish Kumar, Chandra Prakash Prasad","doi":"10.1177/03008916261437964","DOIUrl":"https://doi.org/10.1177/03008916261437964","url":null,"abstract":"<p><p>Intratumor heterogeneity (ITH) describes the diversity of cancer cells within a single tumor. This heterogeneity includes differences in the cells' phenotypes, genotypes, and functions. As a result, cancer cells can vary in their morphology, gene expression and protein profiles, metabolic behavior, and their ability to proliferate and invade surrounding tissues. As a hallmark of cancer, ITH presents major obstacles to the effective treatment of solid tumors by contributing to therapeutic resistance, increased metastatic potential, and higher relapse rates. ITH arises from multiple factors, including genetic instability, epigenetic modifications, selective pressures from the tumor microenvironment, and therapy-induced selection. Individually or collectively, these factors alter the transcriptomic and proteomic landscapes of cancer cells, driving heterogeneity and enabling them to adapt, survive, and evolve under hostile growth conditions. Despite its clinical relevance, the holistic understanding of ITH is still a challenge. Various biophysical techniques are being employed to gain a deeper insight of ITH. Importantly, the intricate nature of ITH implies that existing therapies primarily eliminate dominant clones, unintentionally permitting minor subclones to survive and contribute to disease relapse and therapeutic resistance. Thus, developing strategies that combine adaptive multi-agent therapies with functional analysis of subclonal dynamics is anticipated to drive substantial improvements in precision oncology, paving the way toward personalized and durable cancer care. The present study discusses ITH in-depth, describes the genetic, epigenetic, microenvironmental, and therapy-induced factors that contribute to its definition, assesses current analytical techniques, and considers ways to mitigate its impact on cancer treatment.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261437964"},"PeriodicalIF":3.1,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of bio-psycho-social factors on mental health outcomes in patients with solid tumors.","authors":"Raffaela D G Sartori, Davide Dalu, Davide De Francesco, Valentina Biscaldi, Maria Silvia Cona, Anna Gambaro, Sabrina Ferrario, Lorenzo Ruggieri, Virginio Filipazzi, Cinzia Fasola, Cristina Marrazzo, Nicla La Verde","doi":"10.1177/03008916261442818","DOIUrl":"https://doi.org/10.1177/03008916261442818","url":null,"abstract":"<p><strong>Introduction: </strong>The old oncology approach, which considered the clinical and performance status as the most relevant diseases course and well-being indexes, has been recently replaced by a care system also focusing on a person's characteristics and needs. This study analyzed the role of physical symptoms, illness awareness, individual activities and social contexts on anxious/depressive symptoms and mental health in localized (LP) and advanced/metastatic (AMP) cancer patients.</p><p><strong>Methods: </strong>Socio-demographic and medical information was gathered. The Revised Illness Perception Questionnaire, Hospital and Depression Anxiety Scale, and Mental Health Continuum Short-Form were administered.</p><p><strong>Results: </strong>One hundred and thirteen patients, 75 LP and 38 AMP, aged 27-82, were enrolled. Unique patterns of difficulties and resources emerged at different stages of cancer. AMP reported a worse quality of life in perceived illness persistence and treatments control, anxious/depressive symptoms, and psychological well-being. In LP, higher levels of anxious/depressive symptoms were associated with lack of hobbies, and higher perceived illness control was linked to higher mental health. LP did not report higher well-being than AMP. No significant differences in flourishing persons distributions were detected among groups. A multivariable model showed that the independent presence of pain and partner influenced higher levels of mental health more in AMP than in LP.</p><p><strong>Conclusion: </strong>Tailored intervention should enhance individuals' mental health and active resources mobilization.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261442818"},"PeriodicalIF":3.1,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision animal models of tumors: Advances, challenges and clinical translation.","authors":"Zhengyi Wang, Xiaoying Wu","doi":"10.1177/03008916261427237","DOIUrl":"https://doi.org/10.1177/03008916261427237","url":null,"abstract":"<p><p>Preclinical immunotherapy research relies heavily on animal tumor models, which can be broadly classified into four categories: genetically engineered, carcinogen-induced, spontaneous, and humanized transplantation platforms. While these systems mimic tumorigenesis, immune-microenvironment interactions, and therapeutic responses, their clinical translational utility is limited by species differences, incomplete immune reconstitution, and significant ethical concerns. This review synthesizes current approaches, systematically catalogs their respective strengths and limitations, and proposes integrated solutions that incorporate multi-omics datasets, artificial intelligence modeling, standardized protocols, and international consortia. Future research should prioritize the development of next-generation humanized platforms and virtual digital tumor models, and accelerate clinical translation through rigorous cross-species validation.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261427237"},"PeriodicalIF":3.1,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.","authors":"Alessandro Rametta, Sebastiano Buti, Marco Stellato, Marco Maruzzo, Luca Lalli, Alessandro Acunzo, Michele Maffezzoli, Davide Bimbatti, Francesco Pierantoni, Francesco Massari, Paola Ermacora, Roberto Iacovelli, Alessia Mennitto, Claudia Mucciarini, Matteo Santoni, Lucia Fratino, Rafael Morales, David Marmolejo, Laia Catalan, Cristina Suarez, Giuseppe Procopio","doi":"10.1177/03008916261436580","DOIUrl":"https://doi.org/10.1177/03008916261436580","url":null,"abstract":"<p><strong>Background: </strong>Non-clear cell renal cell carcinoma (nccRCC) represents a heterogeneous group of rare malignancies with limited evidence guiding systemic therapy. The recent introduction of immune checkpoint inhibitors (ICIs) and their combinations with tyrosine kinase inhibitors (TKIs) has shown promising results, but real-world data remain scarce.</p><p><strong>Methods: </strong>We retrospectively collected clinical and pathological data from patients with metastatic nccRCC included in the Italian Meet-URO-23/I-RARE database and from Vall d'Hebron Institute of Oncology (VHIO). Prognostic factors for overall survival (OS) were analyzed using univariate and multivariate Cox regression. Treatment outcomes were assessed by histology and therapeutic regimen.</p><p><strong>Results: </strong>A total of 156 patients were included: papillary (56.4%), chromophobe (22.4%), translocated (10.9%), and unclassified (10.3%) RCC. Median OS was 17.5 months (95%CI 14.7-27.6) and median progression free survival (PFS) 10.2 months (95%CI 7.6-13.7). Patients treated with ICI-combinations (ICI plus ICI or ICI plus VEGF-TKI) showed significantly improved survival (median OS not reached vs 14.7 months for other regimens, p = 0.0053). The overall objective response rate (ORR) and disease free survival (DFS) for ICI+TKI was 53.3% (16/30 evaluable) and 93.3% (28/30), with ORR of 55.5% (10/18) in papillary and 46.1% (6/13) in chromophobe subtypes. In the overall ICI-combination group, ORR was 48%. In multivariate analysis, International Metastatic RCC Database Consortium (IMDC) score, presence of bone metastases, and type of first-line therapy were independently associated with OS.</p><p><strong>Conclusions: </strong>In this large international real-world cohort, ICI-based combinations demonstrated superior outcomes compared to other regimens in metastatic nccRCC. These results reinforce the role of immunotherapy combinations as a preferred first-line approach and confirm the IMDC score as a reliable prognostic tool in this population.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261436580"},"PeriodicalIF":3.1,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic and prognostic role of <i>GPX1</i> in NK/T cell lymphoma.","authors":"Wen Tang, Min Zhao, Juan He, Kuai Yu, Yanmei Tan, Tao Xie, Dan Li","doi":"10.1177/03008916261422175","DOIUrl":"https://doi.org/10.1177/03008916261422175","url":null,"abstract":"<p><strong>Purpose: </strong>Natural killer/T-cell lymphoma (NKTCL) is an aggressive lymphoma. Glutathione peroxidase 1 (<i>GPX1</i>) is a prevalent isoform with reported roles in various tumors and prognostic implications. However, <i>GPX1</i>'s role in NKTCL remains unclear. This study's aim is to explore the association of <i>GPX1</i> expression with NKTCL.</p><p><strong>Methods: </strong>To explore <i>GPX1</i> expression in NKTCL, we employed GEO2R to identify DEGs (Differentially-expressed genes) from GSE80632 (NKTCL and normal samples) in the Gene Expression Omnibus (GEO). Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis was employed to perform the biological processes enrichment. Immunohistochemistry (IHC) confirmed <i>GPX1</i> expression in 76 NKTCL cases. Kaplan-Meier survival curves assessed OS, while Cox regression and Logistic analyses studied <i>GPX1</i>'s clinical associations.</p><p><strong>Results: </strong><i>GPX1</i>, among the top ten of 3362 DEGs, distinguished NKTCL from normal tissue. High <i>GPX1</i> expression correlated with advanced-stage disease and poor initial treatment outcomes. Logistic analysis found no significant clinical feature association. Patients with high <i>GPX1</i> expression had lower OS.</p><p><strong>Conclusion: </strong><i>GPX1</i> could serve as a diagnostic and prognostic biomarker for NKTCL patients.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261422175"},"PeriodicalIF":3.1,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world study.","authors":"Alessandro Leonetti, Vanessa Callegari, Fabiana Perrone, Giuseppe Maglietta, Paola Bordi, Emilio Bria, Emanuele Vita, Francesco Gelsomino, Andrea De Giglio, Alain Gelibter, Marco Siringo, Francesca Mazzoni, Enrico Caliman, Carlo Genova, Giulia Barletta, Federica Bertolini, Giorgia Guaitoli, Francesco Passiglia, Marco Donatello Delcuratolo, Michele Montrone, Sara Oresti, Giulia Pasello, Elisa Roca, Lorenzo Belluomini, Fabiana Letizia Cecere, Annalisa Guida, Anna Manzo, Alessandro Russo, Francesca Rastelli, Alessandra Bulotta, Fabrizio Citarella, Luca Toschi, Federica Zoratto, Diego Luigi Cortinovis, Francesco Paoloni, Alessandro Follador, Annamaria Carta, Andrea Camerini, Flavio Salerno, Rosa Rita Silva, Editta Baldini, Corrado Ficorella, Matteo Brighenti, Matteo Santoni, Francesco Malorgio, Caterina Caminiti, Matteo Puntoni, Marcello Tiseo","doi":"10.1177/03008916261443123","DOIUrl":"10.1177/03008916261443123","url":null,"abstract":"<p><p>IntroductionChemo-immunotherapy is the standard frontline treatment of advanced non-squamous non-small cell lung cancer (nsq-NSCLC). Among oncogenic drivers, KRAS mutation accounts for approximately 25% of lung adenocarcinomas, with p.G12C being the most common variant. This study assessed clinical features and survival outcomes according to KRAS mutation in a real-life population of nsq-NSCLC patients treated with first-line platinum-pemetrexed-pembrolizumab.MethodsThis is a retrospective-prospective study including patients with nsq-NSCLC who received first-line platinum-pemetrexed-pembrolizumab from 4 September 2018 in 33 Italian Centers.ResultsAmong the 765 patients included in this analysis, 121 (15.8%) had <i>KRAS</i> p.G12C mutation, 201 (26.3%) <i>KRAS</i> non-p.G12C mutation and 443 (57.9%) <i>KRAS</i> WT. <i>KRAS</i>-mutated patients had more frequently a history of smoking (90.6% vs 84.1%, p=0.012) and bone metastases (44.1% vs 35.9%; p=0.022) compared to <i>KRAS</i> WT.Median Overall Survival (OS) was similar between <i>KRAS</i>-mutated and <i>KRAS</i> WT patients (16.7 vs 18.2 months; adjusted Hazard Ratio [HR] 1.19, 95% Confidence Interval [CI] 0.95-1.50, p=0.132). No difference in OS was found between <i>KRAS</i> p.G12C and <i>KRAS</i> non-p.G12C (15.9 vs 17.0 months, HR 0.93, 95% CI: 0.66-1.31, p=0.676).Median progression-free survival was significantly shorter in <i>KRAS</i>-mutated compared to <i>KRAS</i> WT patients (8.8 vs 10.8 months; adjusted HR 1.29, 95% CI 1.04-1.59, p=0.018), with no differences between <i>KRAS</i> p.G12C and <i>KRAS</i> non-p.G12C (8.8 vs 8.8 months, HR 0.95, 95% CI: 0.70-1.30, p=0.756).Conclusions<i>KRAS</i> mutation showed a potential negative predictive role in advanced nsq-NSCLC treated with first-line chemo-immunotherapy. The impact of co-mutations and post-progression outcomes warrants further investigation.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261443123"},"PeriodicalIF":3.1,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolution of cinematic language in portraying cancer.","authors":"Andrea Ferrari, Cristiano Nardò, Tobia Passigato, Elena Pagani Bagliacca, Matteo Silva, Alice Patriccioli, Stefano Signoroni, Walter Ferrari Bravo, Michela Casanova, Maura Massimino","doi":"10.1177/03008916261442817","DOIUrl":"https://doi.org/10.1177/03008916261442817","url":null,"abstract":"<p><p>Drawing inspiration from the sitcom <i>Ho Preso un Granchio</i> created by the young patients of the Youth Project at the Istituto Nazionale dei Tumori in Milan, this paper discusses how the depiction of cancer in film and television has changed over the years: specifically, how in 50 years society has gone from being unable to even pronounce the word \"cancer\" to being able to laugh about it, much like they did, telling their own stories with self-irony and even black humor.These reflections are the result of meetings held with the Youth Project patients, who for this initiative reinvented themselves as authors, screenwriters, actors, and assistant directors.This article serves as a reminder that film and television are a mass art form that acts as a mirror of our society, but at the same time can profoundly influence the collective imagination and the ways we express ourselves and think. Like other art forms, cinema can play an important role in narrating the illness of cancer, but it can also be used to support the disease journey of oncology patients, as in the creative laboratories of the Youth Project, where art becomes the tool to offer young patients a way to open up and tell their stories, their fears, and their hopes.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261442817"},"PeriodicalIF":3.1,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethical challenges and multidisciplinary approaches in end-of-life oncology care: Insights from the 2025 AIOM Ethics Days.","authors":"Lorenzo Belluomini, Angela Toss, Massimo Di Maio, Francesco Perrone, Vittorina Zagonel","doi":"10.1177/03008916261431067","DOIUrl":"https://doi.org/10.1177/03008916261431067","url":null,"abstract":"<p><p>End-of-life care in oncology represents a complex and multidimensional challenge that requires ethical awareness, effective communication, and multidisciplinary collaboration. Drawing from the discussions and data presented during the 2025 AIOM Ethics Days, this paper highlights key aspects influencing the quality and humanity of end-of-life care. Significant gaps persist in clinicians' knowledge and in the practical implementation of shared care planning, not solved by the dedicated Italian law approved in 2017 (n.219). Communication between oncologists and patients remains a critical factor in fostering informed decisions and emotional support. Awareness of prognosis and early integration of palliative care improve quality of life, yet these remain underutilized. Spiritual support and organizational innovation are increasingly recognized as essential components of comprehensive care. The findings highlight the importance of interprofessional dialogue, ethical reflection, and ongoing education to reduce overtreatment and professional distress. Fostering a culture of respect and shared responsibility is essential to uphold patients' dignity throughout the end-of-life process.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261431067"},"PeriodicalIF":3.1,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147780893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breath analysis for non-invasive detection of breast cancer: A prospective observational cohort study.","authors":"Michela Bianchi, Francesco Segrado, Alessio Polymeropoulos, Andreina Oliverio, Paolo Baili, Luisa Emma Morandi, Roberto Agresti, Gianfranco Scaperrotta, Siranoush Manoukian, Manuela Milani, Valerio Leoni, Rosalba Miceli, Patrizia Pasanisi, Rosaria Orlandi","doi":"10.1177/03008916261431054","DOIUrl":"https://doi.org/10.1177/03008916261431054","url":null,"abstract":"<p><strong>Purpose and design: </strong>BreathBC is a multicenter prospective observational cohort study aimed at comparing metabolic profiles from exhaled breath of patients with breast cancer (BC) and malignancy-free controls. The study accounts for the novelty and complexity of breath analysis, with a particular emphasis on the standardization of each step in the process.</p><p><strong>Participants: </strong>Women with primary BC without distant metastasis, women carriers of germline BRCA1/2 pathogenic variants and controls were consecutively recruited in two clinical independent cohorts and two technical validation cohorts. Breath samples were collected and linked to clinical breast status, personal, medical and lifestyle data that were retrieved using a questionnaire focused on factors potentially affecting breath analysis.</p><p><strong>Results: </strong>Among 1010 participants, a group of 846 subjects, compliant with criteria of recruitment and sampling of the study, were preliminarily characterized. The mean age was 61 years for patients with BC and 58 years for controls, with 71% of women in post-menopause. The control group included 48% of participants with benign disease. Hypertension was the main age-related morbidity observed in 28% of participants and 10% were smokers. Among patients with BC, 15% had <i>in situ</i> disease and 85% an invasive cancer whose sub-typing presented a high prevalence of luminal subtypes, in agreement with the consecutive recruitment.Future activities will be focused on data analysis of breathomics data and on technical enhancement of prototypes used for sampling and instrumental analysis.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261431054"},"PeriodicalIF":3.1,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147782353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey among childhood cancer survivors about their preferences on functionalities of a to-be-developed Survivorship Passport Mobile App.","authors":"Sara Oberti, Giorgia Manuzi, Martina Fragola, Hannah Gsell, Monica Muraca, Andrea Beccaria, Anita Kienesberger, Carina Schneider, Zuzana Tomasikova, Jack Latteur, Leontien C M Kremer, Riccardo Haupt, Ramona Tallone","doi":"10.1177/03008916261425443","DOIUrl":"https://doi.org/10.1177/03008916261425443","url":null,"abstract":"<p><strong>Objective: </strong>Investigate preferences of childhood cancer survivors (CCS) or of their caregivers (CG) about functionalities of a to be developed mobile app intended to improve compliance with a personalized survivorship care plan (Survivorship Passport) delivered according to the PanCareFollowUp model.</p><p><strong>Study setting and design: </strong>A 19-item Likert-type questionnaire was distributed by Childhood Cancer International among its affiliated associations. App functionalities were grouped into four modules (My Passport; My Hospital; Communication/Telehealth; My Health) and assigned to one of the Quality of cancer Survivorship Care Framework (QCSCF) domains.Data source and analytic sample:A decreasing score was given to each answer with \"very useful\" having the score of 4 and \"not useful\" the score of 1. Response data were reported with their mean (μ) score and values >3.5, between 3.2 - 3.5, 2.6 - 3.1 and <3.1 were defined as \"very appreciated\" \"appreciated\", \"fairly appreciated\" and \"not appreciated\", respectively.</p><p><strong>Principal findings: </strong>One hundred and fifty-four subjects (55% CG) completed the survey. Six functionalities were very appreciated and belonged either to the My Passport (n=3), My Hospital (n=2) or Communication/Telehealth (n=1) modules. Nine functionalities were appreciated (Communication/Telehealth n=6, My Passport n=3). Functionalities of the My Health module were the least appreciated. When functionalities were pooled according to the QCSCF, those pertinent to the health care delivery contextual domain were very appreciated, while those related to cancer and its treatment were not appreciated.</p><p><strong>Conclusions: </strong>This survey provided useful information which contributed to the development of the Cancer Survio Smart Card prototype by the SmartCARE consortium.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"3008916261425443"},"PeriodicalIF":3.1,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147782154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}